TOxicity Reduction using Proton bEam therapy for Oropharyngeal cancer

A phase III trial of intensity-modulated proton beam therapy versus intensity-modulated radiotherapy for multi-toxicity reduction in oropharyngeal cancer

Disease site: Head and neck cancer

Treatment modality: Other: Proton beam therapy

Status: Open to recruitment

Trial details

TORPEdO is a phase III, multicentre, randomised trial to assess whether intensity modulated proton therapy (IMPT) compared with intensity modulated radiotherapy treatment (IMRT) reduces toxicity in oropharyngeal squamous cell carcinoma.

183 patients will be recruited from UK sites over a 3.5 year period, with patients randomised to IMPT being treated at either The Christie NHS Foundation Trust or University College London Hospitals NHS Foundation Trust. Patients will receive treatment for 6.5 weeks, and will be followed up for a further 5 years.

Further information for potential participants

Patient Information Sheet

Further information for healthcare professionals

Protocol

Further information 

Chief Investigator: Dr David Thomson, The Christie NHS Foundation Trust

ICR-CTSU Scientific Lead: Professor Emma Hall

Trial management contact: [email protected]

ISRCTN: 16424014

Sponsor: The Institute of Cancer Research

Funding: Cancer Research UK (CRUK/18/010) and The Taylor Family Foundation

View TORPEdO on the National Institute for Health Research website: NIHR - Be Part Of Research

A lay summary in plain English is available from Cancer Research UK

Publications and presentations

TORPEdO – A Phase III Trial of Intensity-modulated Proton Beam Therapy Versus Intensity-modulated Radiotherapy for Multi-toxicity Reduction in Oropharyngeal Cancer. Price J, Hall E, West C, Thomson D. Clin Oncol (R Coll Radiol). 2019 Oct 8.

Patient Involvement in the Design of a Phase III Trial Comparing Intensity-modulated Proton Therapy and Intensity-modulated Radiotherapy for Oropharyngeal Cancer. Hague C, et al. Clin Oncol (R Coll Radiol). 2018 May;30(5):274-276